CDK Inhibitors

CDK1

CDK2

CDK3

CDK4

CDK5

CDK6

CDK7

CDK8

CDK9

CDK11

CDK12

CDK13

CDK14

CDK16

CDK19

CDC

CLK

Pho85

CDK10

CDK15

CDK17

CDK18

CDK20

PITSLRE

CDK Degraders, Inhibitors, Agonists, Antagonists & Activators

Product Name	CDK1	CDK2	CDK3	CDK4	CDK5	CDK6	CDK7	CDK8	CDK9	CDK11	CDK12	CDK13	CDK14	CDK16	CDK19	CDC	CLK	Pho85	CDK10	CDK15	CDK17	CDK18	CDK20	PITSLRE	Purity
Palbociclib				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.94%
Abemaciclib	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	CDK5/p35, IC₅₀: 287 nM Cdk5/p25, IC₅₀: 355 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM																99.97%
Ro-3306	CDK1, Ki: 20 nM CDK1/cyclinB1, Ki: 35 nM CDK1/cyclin A, Ki: 110 nM	CDK2/cyclinE, Ki: 340 nM																							99.83%
Ribociclib				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.94%
Dinaciclib	CDK1, IC₅₀: 3 nM	CDK2, IC₅₀: 1 nM			CDK5, IC₅₀: 1 nM				CDK9, IC₅₀: 4 nM																99.80%
KI-CDK9d-32									CDK9, DC₅₀: 0.89 nM																98.99%
CDK6/PIM1-IN-1 hydrochloride				CDK4, IC₅₀: 3.6 nM		CDK6, IC₅₀: 39 nM																			99.38%
CGP-74514	CDK1/cyclinB1, IC₅₀: 25 nM
Flavopiridol	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM																					99.73%
GSK3326595				CDK4		CDK6																			99.83%
(R)-Roscovitine	cdc2/cyclin B, IC₅₀: 0.65 μM	cdk2/cyclin A, IC₅₀: 0.7 μM Cdk2/cyclin E2, IC₅₀: 0.7 μM			CDK5/p35, IC₅₀: 0.16 μM																				99.53%
Palbociclib monohydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.98%
THZ1							CDK7, IC₅₀: 3.2 nM																		99.84%
Palbociclib hydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.89%
AZD4573									CDK9, IC₅₀: 4 nM																99.98%
Palbociclib isethionate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.95%
THZ531							CDK7, IC₅₀: 8.5 μM		CDK9, IC₅₀: 10.5 μM		CDK12, IC₅₀: 158 nM	CDK13, IC₅₀: 69 nM													99.86%
Abemaciclib methanesulfonate	CDK1/cyclinB1, IC₅₀: 1627 nM	CDK2/cyclinE, IC₅₀: 504 nM		Cdk4/cyclin D1, IC₅₀: 2 nM	Cdk5/p25, IC₅₀: 355 nM CDK5/p35, IC₅₀: 287 nM	CDK6/cyclinD1, IC₅₀: 10 nM	CDK7/Mat1/cyclinH1, IC₅₀: 3910 nM		CDK9/cyclinT1, IC₅₀: 57 nM																99.95%
Wogonin								CDK8																	99.92%
Kenpaullone	Cdk1/cyclin B, IC₅₀: 0.4 μM	cdk2/cyclin A, IC₅₀: 0.68 μM CDK2/cyclinE, IC₅₀: 7.5 μM			Cdk5/p25, IC₅₀: 0.85 μM																				98.20%
SR-4835											CDK12, IC₅₀: 99 nM CDK12, Kd: 98 nM	CDK13, Kd: 4.9 nM													99.73%
SNS-032	CDK1, IC₅₀: 480 nM	CDK2, IC₅₀: 38 nM		CDK4, IC₅₀: 925 nM			CDK7, IC₅₀: 62 nM		CDK9, IC₅₀: 4 nM																99.54%
Tagtociclib hydrate		CDK2/cyclin E1, Ki: 1.16 nM																							99.73%
SY-5609		CDK2, Ki: 2600 nM					CDK7, Kd: 0.065 nM		CDK9, Ki: 960 nM		CDK12, Ki: 870 nM														99.33%
Toyocamycin		CDK2/cyclinA, IC₅₀: 0.67 μM		Cdk4/cyclin D3, IC₅₀: 15 μM		cdk6/cyclin D3, IC₅₀: >10 μM	CDK7/Mat1/cyclinH1, IC₅₀: 2.8 μM		CDK9/cyclinT1, IC₅₀: 79 nM																99.78%
GSK 3 Inhibitor IX	Cdk1/cyclin B, IC₅₀: 320 nM	cdk2/cyclin A, IC₅₀: 300 nM		Cdk4/cyclin D1, IC₅₀: 10 μM	CDK5/p35, IC₅₀: 80 nM																				99.73%
OTS964 hydrochloride										CDK11B, Kd: 40 nM															99.74%
NVP-2									CDK9, IC₅₀: 0.5 nM																99.60%
hSMG-1 inhibitor 11j	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																							99.82%
Samuraciclib hydrochloride	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.98%
Amantadine		CDK2																							99.90%
Simurosertib																Cdc7, IC₅₀: <0.3 nM									99.94%
JNJ-7706621	Cdk1/cyclin B, IC₅₀: 9 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM	CDK3/Cyclin E, IC₅₀: 58 nM	Cdk4/cyclin D1, IC₅₀: 253 nM		CDK6/cyclinD1, IC₅₀: 175 nM																			99.91%
AT7519	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM																99.76%
CPS2		CDK2, IC₅₀: 24 nM																							99.33%
BI-1347								CDK8, IC₅₀: 1.1 nM																	99.84%
MBQ-167																Cdc42, IC₅₀: 78 nM									99.64%
TG003																	CLK1, IC₅₀: 20 nM CLK2, IC₅₀: 200 nM CLK4, IC₅₀: 15 nM								99.57%
Enitociclib									CDK9/CycT1, IC₅₀: 3 nM																99.89%
AZD-5438	cdk1-cyclin B1, IC₅₀: 16 nM	cdk2-cyclin E, IC₅₀: 6 nM cdk2-cyclin A, IC₅₀: 45 nM		cdk4-cyclin D1, IC₅₀: 449 nM	cdk5-p25, IC₅₀: 14 nM	cdk6-cyclin D3, IC₅₀: 21 nM	cdk7-cyclin H, IC₅₀: 821 nM		cdk9-cyclin T, IC₅₀: 20 nM																99.91%
KB-0742 dihydrochloride	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	CDK4/cyclin D, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cyclinD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM	CDK8/cyclin C, IC₅₀: >10000 nM	CDK9/cyclinT1, IC₅₀: 6 nM																99.24%
AS2863619								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM										99.94%
YKL-5-124		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM																98.79%
Ribociclib hydrochloride				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.95%
BSJ-4-116											CDK12, IC₅₀: 6 nM														98.73%
Ribociclib succinate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.93%
Flavopiridol Hydrochloride	CDK1/Cyc B1, IC₅₀: 30 nM	CDK2/Cyc E, IC₅₀: 170 nM		CDK4/Cyc D1, IC₅₀: 100 nM																					99.73%
CLK-IN-T3																	CLK1, IC₅₀: 0.67 nM CLK2, IC₅₀: 15 nM CLK3, IC₅₀: 110 nM								98.63%
CVT-313	Cdk1/cyclin B, IC₅₀: 4.2 μM	cdk2/cyclin A, IC₅₀: 0.5 μM		Cdk4/cyclin D1, IC₅₀: 215 μM																					99.90%
Fadraciclib		CDK2							CDK9																99.78%
(R)-CR8	Cdk1/cyclin B, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM																99.61%
SLK/STK10-IN-1																	CLK2, IC₅₀: 39 nM								99.78%
hSMG-1 inhibitor 11e	CDK1, IC₅₀: 32 μM	CDK2, IC₅₀: 7.1 μM																							99.94%
Romaciclib monohydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM										99.29%
NG 52	cdc2-cyclin B, IC₅₀: 0.34 μM				Pho85p, IC₅₀: 2 nM																				99.88%
BTX-A51							CDK7, Kd: 1.3 nM		CDK9, Kd: 4 nM																98.58%
Ebvaciclib		CDK2, Ki: 0.09 nM		CDK4, Ki: 0.13 nM		CDK6, Ki: 0.16 nM																			99.98%
NU6300		CDK2																							98.44%
Nimbolide				CDK4		CDK6																			99.79%
TL12-186		cdk2/cyclin A, IC₅₀: 73 nM							CDK9/cyclinT1, IC₅₀: 55 nM																99.63%
BSJ-03-204				CDK4/D1, IC₅₀: 26.9 nM		CDK6/D1, IC₅₀: 10.4 nM																			99.76%
BSJ-04-132				CDK4/D1, IC₅₀: 50.6 nM		CDK6/D1, IC₅₀: 30 nM																			99.07%
MSC2530818								CDK8, IC₅₀: 2.6 nM																	99.62%
PROTAC CDK2/9 Degrader-1		CDK2, DC₅₀: 62 nM							CDK9, DC₅₀: 33 nM																99.85%
CGP60474	CDK1-Cyclin B, IC₅₀: 26 nM	CDK2/cyclinE, IC₅₀: 3 nM cdk2/cyclin A, IC₅₀: 4 nM		CDK4/cyclin D, IC₅₀: 216 nM	Cdk5/p25, IC₅₀: 10 nM		CDK7/cyclin H, IC₅₀: 200 nM		CDK9/cycT, IC₅₀: 13 nM																98.90%
Mevociclib							CDK7																		99.27%
Amantadine hydrochloride		CDK2																							≥98.0%
PF 477736	CDK1, Ki: 9.9 μM																								99.21%
(E/Z)-Zotiraciclib		CDK2, IC₅₀: 13 nM																							99.96%
FMF-04-159-2		CDK2, IC₅₀: 256 nM (in NanoBRET assay)											CDK14/Cyclin Y, IC₅₀: 39.6 nM (in NanoBRET assay)												99.48%
XL413 monohydrochloride																Cdc7, IC₅₀: 3.4 nM									99.65%
Senexin B								CDK8, Kd: 140 nM							CDK19, Kd: 80 nM										99.09%
XY028-140				CDK4		CDK6																			98.52%
THZ1 Hydrochloride							CDK7, IC₅₀: 3.2 nM																		99.06%
T025																	CLK1, Kd: 4.8 nM CLK2, Kd: 0.096 nM CLK3, Kd: 6.5 nM CLK4, Kd: 0.61 nM								99.64%
BSJ-03-123						CDK6																			≥98.0%
AUZ 454		CDK2(C118L/A144C), Kd: 9.7 nM CDK2(A144C), Kd: 15.4 nM CDK2(C118L), Kd: 18.6 nM CDK2(WT), Kd: 50 nM CDK2(C118L/A144C-Cyclin B), Kd: 134.1 nM																							99.15%
Senexin A								CDK8, Kd: 0.83 μM CDK8, IC₅₀: 280 nM							CDK19, Kd: 0.31 μM										99.79%
R547	Cdk1/cyclin B, Ki: 2 nM Cdk1/cyclin B, IC₅₀: 0.2 nM	CDK2/cyclinE, Ki: 3 nM cdk2/cyclin A, IC₅₀: 0.1 nM CDK2/cyclinE, IC₅₀: 0.4 nM	CDK3/Cyclin E, IC₅₀: 0.8 nM	CDK4/cyclin D, Ki: 1 nM	CDK5/p35, IC₅₀: 0.1 nM	cdk6/cyclin D3, IC₅₀: 4 nM	CDK7/cyclin H, IC₅₀: 171 nM																		99.57%
LDC000067	cdk1-cyclin B1, IC₅₀: 5513 nM	cdk2-cyclin A, IC₅₀: 2441 nM		cdk4-cyclin D1, IC₅₀: 9242 nM					CDK9- Cyclin T1, IC₅₀: 44 nM																99.00%
Cucurbitacin E	cyclin B1/CDC2																								99.92%
PHA-767491 hydrochloride	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM																99.49%
CTX-712																	CLK2, IC₅₀: 1.4 nM								98.15%
CCT-251921								CDK8, IC₅₀: 2.3 nM							CDK19, IC₅₀: 2.6 nM										99.01%
Milciclib	cyclin B/CDK1, IC₅₀: 398 nM	cyclin A/CDK2, IC₅₀: 45 nM cyclin E/CDK2, IC₅₀: 363 nM		cyclin D1/CDK4, IC₅₀: 160 nM			cyclin H/CDK7, IC₅₀: 150 nM																		99.90%
Purvalanol A	cdc2-cyclin B, IC₅₀: 4 nM	cdk2-cyclin E, IC₅₀: 35 nM cdk2-cyclin A, IC₅₀: 70 nM		cdk4-cyclin D1, IC₅₀: 850 nM	cdk5-p35, IC₅₀: 75 nM																				98.61%
Atuveciclib	CDK1/CycB(h), IC₅₀: 1100 nM	CDK2/CycE(h), IC₅₀: 1000 nM	CDK3/CycE(h), IC₅₀: 890 nM		CDK5/p35(h), IC₅₀: 1600 nM				CDK9/CycT1, IC₅₀: 13 nM CDK9/CycT1(h), IC₅₀: 6 nM																99.75%
BMS-265246	CDK1/cycB, IC₅₀: 6 nM	CDK2/Cyc E, IC₅₀: 9 nM		CDK4/cycD, IC₅₀: 230 nM																					99.59%
SU9516	CDK1, IC₅₀: 40 nM	CDK2, IC₅₀: 22 nM		CDK4, IC₅₀: 200 nM																					99.85%
Tambiciclib									CDK9																99.21%
Abemaciclib metabolite M2				CDK4, IC₅₀: 1.2 nM		CDK6, IC₅₀: 1.3 nM																			99.75%
Asnuciclib	CDK1, IC₅₀: 8.17 nM CDK1, Ki: 4 nM	CDK2, IC₅₀: 3.27 nM CDK2, Ki: 3 nM		CDK4, IC₅₀: 8.18 nM		CDK6, IC₅₀: 37.68 nM	CDK7, IC₅₀: 134.26 nM CDK7, Ki: 91 nM		CDK9, IC₅₀: 5.78 nM CDK9, Ki: 4 nM																99.76%
Dalpiciclib				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM																			99.70%
Sinigrin				CDK4		CDK6																			99.97%
(R)-CR8 trihydrochloride	CDK1/cyclinB1, IC₅₀: 0.09 μM	cdk2/cyclin A, IC₅₀: 0.072 μM CDK2/cyclinE, IC₅₀: 0.041 μM			Cdk5/p25, IC₅₀: 0.11 μM		CDK7/cyclin H, IC₅₀: 1.1 μM		CDK9/Cyclin T, IC₅₀: 0.18 μM																98.95%
XL413																Cdc7, IC₅₀: 3.4 nM									99.76%
Roniciclib	Cdk1/cyclin B, IC₅₀: 7 nM	CDK2/cyclinE, IC₅₀: 9 nM		CDK4/cyclin D, IC₅₀: 11 nM			CDK7/Cyclin H/MAT1, IC₅₀: 25 nM		CDK9/cyclinT1, IC₅₀: 5 nM																98.09%
RGB-286638	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM																99.70%
THZ2	CDK1, IC₅₀: 96.9 nM	CDK2, IC₅₀: 222 nM			CDK5, IC₅₀: 134 nM		CDK7, IC₅₀: 13.9 nM	CDK8, IC₅₀: 6830 nM	CDK9, IC₅₀: 194 nM																99.03%
Narazaciclib				Cdk4/cyclin D1, IC₅₀: 3.9 nM		CDK6/cyclinD1, IC₅₀: 9.82 nM																			98.66%
CDK2-IN-4	Cdk1/cyclin B, IC₅₀: 86 μM	cdk2/cyclin A, IC₅₀: 44 nM																							99.85%
Thiabendazole	CCNE1	CDK2																							99.94%
BS-181 hydrochloride	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM																99.93%
TC11	CDK1																								99.55%
Abemaciclib metabolite M18 hydrochloride				CDK4		CDK6																			98.18%
Trilaciclib hydrochloride				Cdk4/cyclin D1, IC₅₀: 1 nM		cdk6/cyclin D3, IC₅₀: 4 nM																			99.69%
CLK1-IN-1																	CLK1, IC₅₀: 2 nM								98.55%
Purvalanol B	cdc2/cyclin B, IC₅₀: 6 nM	cdk2/cyclin A, IC₅₀: 6 nM CDK2/cyclinE, IC₅₀: 9 nM			CDK5/p35, IC₅₀: 6 nM
Voruciclib	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/cyc T2, Ki: 0.626 nM CDK9/CycT1, Ki: 1.68 nM																99.77%
CDK5 inhibitor 20-223		CDK2, IC₅₀: 6.0 nM			CDK5, IC₅₀: 8.8 nM																				99.62%
Lerociclib dihydrochloride	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 832 nM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM																98.51%
GFB-12811		CDK2/CycA, IC₅₀: 211 nM			Cdk5/p25, IC₅₀: 2.3 nM	CDK6, IC₅₀: 3197 nM	CDK7/Cyclin H/MAT1, IC₅₀: 718 nM		CDK9/CycT1, IC₅₀: 894 nM																98.04%
KH-CB19																	CLK1, IC₅₀: 19.7 nM CLK3, IC₅₀: 530 nM								99.31%
LY2857785							CDK7, IC₅₀: 0.246 μM	CDK8, IC₅₀: 0.016 μM	CDK9, IC₅₀: 0.011 μM																99.92%
Alisol B 23-acetate				CDK4		CDK6																			99.65%
Alsterpaullone	Cdk1/cyclin B, IC₅₀: 35 nM	cdk2/cyclin A, IC₅₀: 15 nM CDK2/Cyc E, IC₅₀: 200 nM			CDK5/p35, IC₅₀: 40 nM																				99.85%
Romaciclib hydrochloride								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM										99.98%
FN-1501		cdk2/cyclin A, IC₅₀: 2.47 nM		Cdk4/cyclin D1, IC₅₀: 0.85 nM		CDK6/cyclinD1, IC₅₀: 1.96 nM																			98.72%
CP-10						CDK6, DC₅₀: 2.1 nM																			98.41%
XO44	CDK1	CDK2		CDK4																					99.38%
CDK12-IN-3											CDK12, IC₅₀: 491 nM														99.86%
PHA-793887	Cdk1/cyclin B, IC₅₀: 60 nM	cdk2/cyclin A, IC₅₀: 8 nM CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 62 nM	Cdk5/p25, IC₅₀: 5 nM		CDK7/cyclin H, IC₅₀: 10 nM		CDK9/cyclinT1, IC₅₀: 138 nM																99.25%
CKI-7 free base																Cdc7
JH-XI-10-02								CDK8, IC₅₀: 159 nM																	99.73%
PROTAC CDK9 Degrader-1									CDK9																99.55%
(±)-Enitociclib									CDK9																99.87%
JSH-150	Cdk1/cyclin B, IC₅₀: 1.34 μM	cdk2/cyclin A, IC₅₀: 2.86 μM			Cdk5/p25, IC₅₀: 4.64 μM		CDK7/Cyclin H/MNAT1, IC₅₀: 1.72 μM		CDK9/cyclinT1, IC₅₀: 1 nM				CDK14/Cyclin Y, IC₅₀: 1.68 μM	CDK16/Cyclin Y, IC₅₀: 292 nM											98.66%
NU6102	Cdk1/cyclin B, IC₅₀: 9.5 nM	CDK2/cyclin A3, IC₅₀: 5.4 nM		CDK4, IC₅₀: 1.6 μM																					99.23%
MeBIO	Cdk1/cyclin B, IC₅₀: 55 μM				Cdk5/p25, IC₅₀: >100 μM																				≥98.0%
MC180295	CDK1-Cyclin B, IC₅₀: 138 nM	cdk2-cyclin A, IC₅₀: 233 nM cdk2-cyclin E, IC₅₀: 367 nM	CDK3-Cyclin E, IC₅₀: 399 nM	CDK4-Cyclin D, IC₅₀: 112 nM	cdk5-p35, IC₅₀: 159 nM cdk5-p25, IC₅₀: 186 nM	cdk6-cyclin D3, IC₅₀: 712 nM	CDK7-CycH/MAT1, IC₅₀: 555 nM		CDK9- Cyclin T1, IC₅₀: 5 nM																98.89%
Rafutrombopag (tautomerism)				CDK4		CDK6																			98.33%
Bisindolylmaleimide X hydrochloride		CDK2, IC₅₀: 200 nM																							98.90%
CDK12-IN-2		CDK2, IC₅₀: >100 μM					CDK7, IC₅₀: >10 μM CDK7, IC₅₀: >10 μM		CDK9, IC₅₀: 16 μM		CDK12, IC₅₀: 52 nM														99.36%
AZ5576									CDK9, : <5 nM																99.86%
PROTAC CDK12/13 Degrader-1 TFA											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM													99.12%
ML167			CDK3, IC₅₀: ＞10000 nM														CLK4, IC₅₀: 136 nM CLK1, IC₅₀: 1522 nM CLK2, IC₅₀: 1648 nM								98.62%
YX-2-107						CDK6, IC₅₀: 4.4 nM																			99.22%
BRD6989								CDK8, IC₅₀: ~200 nM recombinant CDK8, IC₅₀: ~0.5 μM							recombinant CDK19, IC₅₀: >30 μM										99.56%
KB-0742	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	Cdk4/cyclin D1, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cyclinD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM		CDK9/cyclinT1, IC₅₀: 6 nM																99.38%
CDK9-IN-1									CDK9/CycT1, IC₅₀: 39 nM																98.52%
Avotaciclib	CDK1																								99.72%
CC-671																	CLK2, IC₅₀: 0.006 μM								99.06%
XY028-133				CDK4		CDK6																			98.62%
Samuraciclib hydrochloride dihydrate	CDK1, IC₅₀: 1.8 μM	CDK2, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 31 μM	CDK7, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.90%
Garcinone C							CDK7																		99.66%
RSS0680	CDK1	CDK2		CDK4		CDK6								CDK16/Cyclin Y											99.85%
DS96432529								CDK8																	99.93%
Riviciclib hydrochloride	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.500 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM																99.08%
AMG 925	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM																			99.02%
(-)-Enitociclib									CDK9																99.85%
CDK12-IN-E9		cdk2/cyclin A, IC₅₀: 932 nM					CDK7/Cyclin H/MNAT1, IC₅₀: 1210 nM		CDK9/cyclinT1, IC₅₀: 23.9 nM																99.71%
CDK9-IN-2									CDK9, IC₅₀: 5 nM (H929 multiple myeloma cell line)																98.72%
Tabersonine				CDK4																					98.14%
Flavone	CDK1/cyclinB1																								99.85%
Abemaciclib metabolite M20				CDK4		CDK6
β-catenin-IN-3				Cdk4/cyclin D1
CDK5-IN-3		CDK2/CycA, IC₅₀: 18 nM			Cdk5/p25, IC₅₀: 0.6 nM																				99.49%
LY3177833																Cdc7, IC₅₀: 3.3 nM									99.48%
CDK9 inhibitor HH1									CDK9																99.69%
Palbociclib-d₈				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM																			99.84%
GW8510		CDK2			CDK5																				99.04%
Ipivivint		CDK2, EC₅₀: 1 nM	CDK3, EC₅₀: 7 nM																						99.95%
YKL-5-124 TFA		CDK2, IC₅₀: 1300 nM					CDK7, IC₅₀: 53.5 nM CDK7/Mat1/CycH, IC₅₀: 9.7 nM		CDK9, IC₅₀: 3020 nM																99.74%
NU6140	CDK1-Cyclin B, IC₅₀: 6.6 μM	cdk2-cyclin A, IC₅₀: 0.41 μM		CDK4-Cyclin D, IC₅₀: 5.5 μM	cdk5-p25, IC₅₀: 15 μM		cdk7-cyclin H, IC₅₀: 3.9 μM																		99.07%
EHT 5372																	CLK1, IC₅₀: 22.8 nM CLK2, IC₅₀: 88.8 nM CLK4, IC₅₀: 59.0 nM								98.12%
Senexin C								CDK8/CycC, IC₅₀: 3.6 nM CDK8/CycC, Kd: 1.4 nM							CDK19/CycC, Kd: 2.9 nM										98.82%
JH-XVI-178								CDK8, IC₅₀: 1 nM							CDK19, IC₅₀: 2 nM										98.87%
Olomoucine		cdk2-cyclin A, IC₅₀: 7 μM cdk2-cyclin E, IC₅₀: 7 μM			cdk5-p35, IC₅₀: 25 μM																				99.87%
CDK2-IN-3		CDK2, IC₅₀: 60 nM
LDC4297							CDK7, IC₅₀: 0.13 nM																		98.14%
Dalpiciclib hydrochloride				CDK4, IC₅₀: 12.4 nM		CDK6, IC₅₀: 9.9 nM																			98.22%
BSJ-01-175											CDK12	CDK13													99.49%
DB0614						CDK6								CDK16/Cyclin Y											98.80%
GSK-3 inhibitor 3		CDK2, IC₅₀: 0.22 μM			CDK5, IC₅₀: 1.3 μM																				98.72%
CDK-IN-2									CDK9/cyclinT1, IC₅₀: 8 nM																99.27%
RGB-286638 free base	cyclin B1-CDK1, IC₅₀: 2 nM	cyclin E-CDK2, IC₅₀: 3 nM	cyclin E-CDK3, IC₅₀: 5 nM	cyclin D1-CDK4, IC₅₀: 4 nM	p35-CDK5, IC₅₀: 5 nM	cyclin D3-CDK6, IC₅₀: 55 nM	cyclin H-CDK7, IC₅₀: 44 nM		T1-CDK9, IC₅₀: 1 nM																98.87%
CDK4/6-IN-15		CDK2, IC₅₀: 3.335 μM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 0.279 μM																			99.32%
K00546	Cdk1/cyclin B, IC₅₀: 0.6 nM	cdk2/cyclin A, IC₅₀: 0.5 nM															CLK1, IC₅₀: 8.9 nM CLK3, IC₅₀: 29.2 nM								98.08%
PHA-767491	CDK1, IC₅₀: 250 nM	CDK2, IC₅₀: 240 nM			CDK5, IC₅₀: 460 nM				CDK9, IC₅₀: 34 nM																99.85%
LL-K8-22								CDK8, DC₅₀: 2.52 μM																	99.76%
Avotaciclib hydrochloride	CDK1																								99.75%
CLK1-IN-3																	CLK1, IC₅₀: 5 nM CLK2, IC₅₀: 42 nM CLK4, IC₅₀: 108 nM								98.54%
CPD-39				CDK4																					98.06%
CDK8-IN-11								CDK8, IC₅₀: 46 nM																	98.20%
AS2863619 free base								CDK8, IC₅₀: 0.61 nM							CDK19, IC₅₀: 4.28 nM										99.87%
CDK9-IN-7				CDK4/cyclin D, IC₅₀: 148 nM		CDK6/cyclinD, IC₅₀: 145 nM			CDK9/cyclinT1, IC₅₀: 11 nM																98.05%
CDK4/6-IN-2				CDK4, IC₅₀: 2.7 nM		CDK6, IC₅₀: 16 nM																			99.67%
TP-1287									CDK9
(E/Z)-Zotiraciclib hydrochloride		CDK2																							99.90%
Ryuvidine				CDK4, IC₅₀: 6.0 μM																					99.40%
Longdaysin							CDK7, IC₅₀: 29 μM																		99.83%
BGG463		CDK2																							≥98.0%
HS-243																	CLK4, IC₅₀: 662 nM								99.95%
FIT-039									CDK9/cyclinT1, IC₅₀: 5.8 μM																99.56%
Atuveciclib Racemate									CDK9																98.48%
YJ1206											CDK12	CDK13
CDDD11-8									CDK9, Ki: 8 nM																99.62%
Avotaciclib trihydrochloride	CDK1																								99.60%
Manzamine A hydrochloride					CDK5, IC₅₀: 1.5 μM																				99.66%
DB1113				CDK4						CDK11B															99.28%
CDK8-IN-13								CDK8, IC₅₀: 51.9 nM																	99.14%
Butyrolactone I	CDK1																								99.80%
AZD5597	CDK1, IC₅₀: 2 nM	CDK2, IC₅₀: 2 nM																							98.09%
LDC4297 hydrochloride							CDK7, IC₅₀: 0.13 nM																		98.23%
NVP-LCQ195	Cdk1/cyclin B, IC₅₀: 2 nM	cdk2/cyclin A, IC₅₀: 2 nM CDK2/cyclinE, IC₅₀: 5 nM	CDK3/Cyclin E, IC₅₀: 42 nM		Cdk5/p25, IC₅₀: 1 nM CDK5/p35, IC₅₀: 1 nM	cdk6/cyclin D3, IC₅₀: 187 nM	CDK7/Cyclin H/MAT1, IC₅₀: 3564 nM		CDK9/cyclinT1, IC₅₀: 15 nM																98.81%
NU2058	CDK1, IC₅₀: 26 μM	CDK2, IC₅₀: 17 μM CDK2, Ki: 12 μM																							99.66%
Lacto-N-fucopentaose I		CDK2/cyclinE																							99.92%
Ribociclib succinate hydrate				CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 39 nM																			99.94%
CDK9-IN-8									CDK9, IC₅₀: 12 nM																99.65%
CDK9-IN-13	CDK1, IC₅₀: 0.14 μM	CDK2, IC₅₀: 0.72 μM					CDK7, IC₅₀: 0.40 μM		CDK9, IC₅₀: <3 nM		CDK12, IC₅₀: 0.055 μM														99.94%
GW297361	yeast Cdk1, IC₅₀: 20 nM human CDK1, IC₅₀: 30 nM	human CDK2, IC₅₀: 1.9 nM		human CDK4, IC₅₀: 300 nM					human CDK9, IC₅₀: 10 nM									yeast Pho85, IC₅₀: 400 nM							98.13%
CDK2-IN-30		CDK2, IC₅₀: ≤ 20 nM																							98.40%
(E/Z)-Zotiraciclib citrate		CDK2																							98.06%
ON-013100				Cdk4/cyclin D1																					99.66%
Casein Kinase inhibitor A86							CDK7, Kd: 0.31 nM		CDK9, Kd: 5.4 nM																99.26%
CDK8/19-IN-1								CDK8/CycC, IC₅₀: 0.46 nM	CDK9, IC₅₀: 270 nM						CDK19/CycC, IC₅₀: 0.99 nM										98.03%
Desmethylglycitein	CDK1	CDK2																							98.98%
DD-03-156																					CDK17				99.90%
CK7		CDK2							CDK9																99.72%
CDK1-IN-2	CDK1, IC₅₀: 5.8 μM																								98.89%
AT7519 Hydrochloride	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM																99.42%
Ca2+ channel agonist 1		CDK2, EC₅₀: 3.34 μM																							99.71%
Cimpuciclib tosylate				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM																			99.65%
Samuraciclib hydrochloride hydrate	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM																99.88%
CDK2 degrader 3		CDK2																							99.91%
CDK9-IN-11									CDK9
HEMTAC CDK4/6 degrader 1				CDK4		CDK6																			98.18%
THZ1-R							CDK7, IC₅₀: 146 nM																		98.06%
CDK2 degrader 5		CDK2																							99.17%
NU6027	CDK1, Ki: 2.5 μM	CDK2, Ki: 1.3 μM																							99.04%
PROTAC CDK12/13 Degrader-1											CDK12, DC₅₀: 2.2 nM	CDK13, DC₅₀: 2.1 nM													98.01%
HTH-01-091							CDK7, IC₅₀: 1230 nM																		98.64%
CDK7-IN-21							CDK7
CDK7-IN-4							CDK7																		98.87%
NecroIr1				CDK4																					98.02%
CDK9-IN-12									CDK9/cyclinT1, IC₅₀: 5.41 nM																99.65%
NSC 625987				CDK4/D1, IC₅₀: 0.2 μM																					98.58%
PROTAC CDK4/6 degrader 1				CDK4, DC₅₀: 10.5 nM		CDK6, DC₅₀: 2.5 nM																			98.88%
CDK1-IN-1	CDK1/cycB, IC₅₀: 161.2 nM																								99.33%
CDK2-IN-31		CDK2
CA224		cdk2-cyclin A, IC₅₀: 521 μM		cdk4-cyclin D1, IC₅₀: 6.2 μM																					99.94%
Lerociclib	CDK1/cyclinB1, IC₅₀: 2.4 μM	cdk2/cyclin A, IC₅₀: 1.5 μM CDK2/cyclinE, IC₅₀: 3.6 μM		Cdk4/cyclin D1, IC₅₀: 1 nM	CDK5/p35, IC₅₀: 0.832 μM Cdk5/p25, IC₅₀: 1.2 μM	cdk6/cyclin D3, IC₅₀: 2 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2.4 μM		CDK9/Cyclin T, IC₅₀: 28 nM																98.35%
BI-1622										CDK11B															98.97%
Voruciclib hydrochloride	CDK1/cycB, Ki: 5.4 nM CDK1/cyc A, Ki: 9.1 nM			CDK4/Cyc D1, Ki: 3.96 nM		CDK6/cycD1, Ki: 2.92 nM			CDK9/CycT1, Ki: 1.68 nM CDK9/cyc T2, Ki: 0.626 nM																99.23%
CDK12-IN-5		CDK2/cyclinE, IC₅₀: 173 μM							CDK9/cyclinT1, IC₅₀: 127 μM		CDK12, IC₅₀: 23.9 nM														99.01%
Abemaciclib metabolite M18				CDK4		CDK6																			98.01%
BS-194	CDK1, IC₅₀: 30 nM	CDK2, IC₅₀: 3 nM			CDK5, IC₅₀: 30 nM		CDK7, IC₅₀: 250 nM		CDK9, IC₅₀: 90 nM																99.36%
TMX-2172		CDK2, IC₅₀: 6.5 nM			CDK5, IC₅₀: 6.8 nM																				99.38%
ABC1183									CDK9- Cyclin T1, IC₅₀: 321 nM																99.62%
BSJ-5-63							CDK7		CDK9		CDK12														99.97%
CDK2 degrader 4		CDK2																							99.71%
7BIO					CDK5																				99.20%
(S)-Roscovitine	CDK1, IC₅₀: ≤1 μM	CDK2, IC₅₀: ≤1 μM			CDK5, IC₅₀: ≤1 μM		CDK7, IC₅₀: ≤1 μM		CDK9, IC₅₀: ≤1 μM																99.15%
CAN508	Cdk1/cyclin B, IC₅₀: 44 μM	CDK2/cyclinE, IC₅₀: 20 μM cdk2/cyclin A, IC₅₀: 69 μM		Cdk4/cyclin D1, IC₅₀: 13.5 μM			CDK7/cyclin H, IC₅₀: 26 μM		CDK9/cyclinT1, IC₅₀: 0.35 μM																99.59%
Cdk5i peptide					Cdk5/p25, Kd: 0.17 μM CDK5, Kd: 15.72 μM																				99.83%
CDK9-IN-10									CDK9																98.09%
KH-CB20																	CLK1, IC₅₀: 16.5 nM CLK3, IC₅₀: 488 nM								99.80%
PNU112455A hydrochloride		CDK2, Km: 3.6 μM			CDK5, Km: 3.2 μM																				99.56%
MU1210																	CLK1, IC₅₀: 8 nM CLK2, IC₅₀: 20 nM CLK4, IC₅₀: 12 nM								99.50%
CDK12-IN-6		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 1.19 μM														98.09%
Vanicoside B			CDK3																						99.82%
Cdk1/2 Inhibitor III	Cdk1/cyclin B, IC₅₀: 0.6 nM	CDK2/cyclinA, IC₅₀: 0.5 nM																							99.69%
5-Iodo-indirubin-3'-monoxime	Cdk1/cyclin B, IC₅₀: 25 nM				Cdk5/p25, IC₅₀: 20 nM																				99.50%
PROTAC CDK9 degrader-9									CDK9																99.25%
CGP-82996	CDK1/cyclinB, IC₅₀: >100 μM	CDK2/cyclinA, IC₅₀: >50 μM CDK2/cyclin E, IC₅₀: >50 μM		Cdk4/cyclin D1, IC₅₀: 1.5 μM CDK4/cyclin D2, IC₅₀: >50 μM	CDK5/p35, IC₅₀: 25 μM	CDK6/cyclinD1, IC₅₀: 5.6 μM Cdk6/cyclin D2, IC₅₀: >50 μM																			98.12%
(R)-DRF053 dihydrochloride	CDK1/cyclinB1, IC₅₀: 220 nM				Cdk5/p25, IC₅₀: 80 nM																				99.30%
(R)-(+)-O-Demethylbuchenavianine	CDK1, IC₅₀: 1.1 μM				CDK5, IC₅₀: 0.95 μM																				98.67%
CDD-2807																	CLK4, IC₅₀: 85 nM CLK2, IC₅₀: 101 nM CLK1, IC₅₀: 116 nM								99.52%
PNU-292137	CDK1/cyclinB, IC₅₀: 270 nM	CDK2/cyclinA, IC₅₀: 37 nM CDK2/cyclin E, IC₅₀: 92 nM		CDK4/cyclinD1, IC₅₀: >10000 nM	Cdk5/p25, IC₅₀: 114 nM																				99.95%
CDK8-IN-1								CDK8, IC₅₀: 3 nM																	99.77%
CDK2-IN-22		CDK2, IC₅₀: 64.42 nM																							98.64%
GSK-3 inhibitor 4		CDK2, IC₅₀: 0.47 μM			CDK5, IC₅₀: 0.68 μM																				98.77%
YKL-1-116							CDK7																		98.67%
PROTAC CDK9 degrader-2									CDK9, IC₅₀: 17 μM (MCF-7 cells)																98.34%
CDK9-IN-14									CDK9, IC₅₀: 6.92 nM																99.91%
RGB-286147	CDK1/cyclinB, IC₅₀: 48 nM	CDK2/E, IC₅₀: 15 nM		CDK4/D1, IC₅₀: 839 nM		cdk6/cyclin D3, IC₅₀: 232 nM																			98.60%
CDK4-IN-3				CDK4, IC₅₀: 25 nM																					98.07%
CDK8 ligand 1								CDK8																	≥98.0%
CDK4/6-IN-12				CDK4, IC₅₀: 592.3 nM		CDK6, IC₅₀: 3090 nM
NSC693868	Cdk1/cyclin B, IC₅₀: 600 nM				Cdk5/p25, IC₅₀: 400 nM																				≥99.0%
Isosilybin B		CDK2		CDK4																					99.32%
CDK1-IN-6	CDK1																								99.96%
TMX-2039	CDK1, IC₅₀: 2.6 nM	CDK2, IC₅₀: 1.0 nM		CDK4, IC₅₀: 52.1 nM	CDK5, IC₅₀: 0.5 nM	CDK6, IC₅₀: 35 nM	CDK7, IC₅₀: 32.5 nM		CDK9, IC₅₀: 25 nM																99.42%
ZLC491											CDK12	CDK13
NecroIr2				CDK4																					98.99%
CLK1/2-IN-1																	CLK1, IC₅₀: 16 nM CLK2, IC₅₀: 45 nM								99.87%
AT7519 TFA	Cdk1/cyclin B, IC₅₀: 210 nM	cdk2/cyclin A, IC₅₀: 47 nM		Cdk4/cyclin D1, IC₅₀: 100 nM	CDK5/p35, IC₅₀: 13 nM	cdk6/cyclin D3, IC₅₀: 170 nM	CDK7/Cyclin H/MAT1, IC₅₀: 2400 nM		CDK9/Cyclin T, IC₅₀: 10 nM
CDK7-IN-1							CDK7, IC₅₀: 100 nM																		98.91%
Romaciclib								CDK8/CycC, IC₅₀: 4.4 nM	CDK9/cycT, IC₅₀: 1070 nM						CDK19/CycC, IC₅₀: 10.4 nM
BS-181	CDK1/cycB, IC₅₀: 8.1 μM	CDK2/Cyc E, IC₅₀: 0.88 μM		CDK4/Cyc D1, IC₅₀: 33 μM	CDK5/p35NCK, IC₅₀: 3 μM	CDK6/cycD1, IC₅₀: 47 μM	CDK7/CycH/MAT1, IC₅₀: 0.021 μM		CDK9/cycT, IC₅₀: 4.2 μM																98.10%
(S)-LY3177833 hydrate																Cdc7
LY3177833 monhydrate																Cdc7, IC₅₀: 3.3 nM									99.76%
IV-361		CDK2, Ki: ≥1000 nM					CDK7, Ki: ≤50 nM																		99.60%
YJ9069											CDK12	CDK13
Akt1&PKA-IN-2		CDK2^a, IC₅₀: 0.69 μM
Manzamine A					CDK5, IC₅₀: 1.5 μM																				98.2%
CPD-10				CDK4
JSH-009 dimaleate	CDK1/cyclinB, IC₅₀: 5410 nM	CDK2/cyclinA, IC₅₀: 6850 nM	CDK3/cyclin E1, IC₅₀: >10,000 nM		Cdk5/p25, IC₅₀: 6950 nM		CDK7/Cyclin H/MNAT1, IC₅₀: 3700 nM	CDK8/cyclin C, IC₅₀: >10,000 nM	CDK9/cyclinT1, IC₅₀: 0.928 nM	CDK11, IC₅₀: >10,000 nM			CDK14/Cyclin Y, IC₅₀: 2710 nM	CDK16/Cyclin Y, IC₅₀: 195 nM
CDK1/Cyc B-IN-1	CDK1-Cyclin B, IC₅₀: 97 nM																								98.47%
CDK9/EZH2-IN-1									CDK9, IC₅₀: 83.9 nM
Bohemine		CDK2/cyclinE, IC₅₀: 4.6 μM cdk2/cyclin A, IC₅₀: 83 μM							CDK9/cyclinT1, IC₅₀: 2.7 μM																98.93%
CDK6/PIM1-IN-1	CDK1/cyclinB, IC₅₀: >10 μM	CDK2/cyclinA, IC₅₀: 2.274 μM	CDK3/Cyclin E, IC₅₀: >10 μM	Cdk4/cyclin D1, IC₅₀: 3.6 nM	Cdk5/p25, IC₅₀: >10 μM	CDK6/cyclinD1, IC₅₀: 39 nM	CDK7/Cyclin H/MNAT1, IC₅₀: 393 nM		CDK9/cyclinT1, IC₅₀: 440 nM		CDK12/Cyclin K, IC₅₀: >10 μM	CDK13/Cyclin K, IC₅₀: >10 μM
Multi-target kinase inhibitor 2		CDK2, IC₅₀: 204 nM																							99.82%
CDK4/6-IN-9						CDK6/cyclinD1, IC₅₀: 905 nM
CDK4 degrader 1				CDK4
LA-CB1				CDK4		CDK6
CDK8-IN-12								CDK8, Ki: 14 nM																	99.74%
CDK2-IN-40		CDK2/cyclinE, IC₅₀: 10 nM
(E/Z)-BIO-acetoxime	CDK1/cyclinB, IC₅₀: 63 μM	CDK2/cyclinA, IC₅₀: 4.3 μM			Cdk5/p25, IC₅₀: 2.4 μM
AMG 925 (HCl)	CDK1, IC₅₀: 1.9 μM	CDK2, IC₅₀: 375 nM		CDK4, IC₅₀: 3 nM		CDK6, IC₅₀: 8 nM
CDK5-IN-1					CDK5																				98.47%
PT-262		CDK2																							99.21%
Sinigrin hydrate				CDK4		CDK6																			99.77%
Abemaciclib metabolite M20-d₈				CDK4		CDK6																			99.26%
Akt1&PKA-IN-1		CDK2, IC₅₀: 9.8 μM
CDK2/4/6-IN-2		CDK2		CDK4		CDK6																			98.20%
JA397													CDK14/Cyclin Y, EC₅₀: 27.1 nM	CDK16/Cyclin Y, EC₅₀: 39.0 nM
Palbociclib dihydrochloride				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Palbociclib orotate				Cdk4/cyclin D3, IC₅₀: 9 nM Cdk4/cyclin D1, IC₅₀: 11 nM		Cdk6/cyclin D2, IC₅₀: 16 nM
Cimpuciclib				CDK4, IC₅₀: 0.49 nM		CDK6, IC₅₀: 9.56 nM
CDK1-IN-5	CDK1, IC₅₀: 42.19 nM	CDK2, IC₅₀: 188.71 nM			CDK5, IC₅₀: 354.15 nM
Samuraciclib	CDK1, IC₅₀: 1.8 μM	CDK2/cycE1, IC₅₀: 578 nM		CDK4, IC₅₀: 49 μM	CDK5, IC₅₀: 9.4 μM	CDK6, IC₅₀: 34 μM	CDK7/CycH/MAT1, IC₅₀: 41 nM		CDK9, IC₅₀: 1.2 μM
ZLMT-12		CDK2, IC₅₀: 0.011 μM							CDK9, IC₅₀: 0.002 μM
CDK7-IN-2 hydrochloride hydrate							CDK7
BS-181 dihydrochloride		CDK2, IC₅₀: 880 nM			CDK5, IC₅₀: 3000 nM		CDK7, IC₅₀: 21 nM		CDK9, IC₅₀: 4200 nM
CDK1-IN-3	CDK1, IC₅₀: 36.8 nM	CDK2, IC₅₀: 305.17 nM			CDK5, IC₅₀: 369.37 nM
CDK4/6-IN-3	CDK1, Ki: 110 nM			CDK4, Ki: 0.3 nM		CDK6, Ki: 2.2 nM
HDAC1/2 and CDK2-IN-1		CDK2, IC₅₀: 0.80 nM
FN-1501-propionic acid		CDK2							CDK9
OTS964										CDK11B, Kd: 40 nM
CDK6/9-IN-1						CDK6, IC₅₀: 40.5 nM			CDK9, IC₅₀: 39.5 nM
Amantadine sulfate		CDK2
CDK7-IN-11							CDK7, IC₅₀: 4.2 nM
Senexin A hydrochloride								CDK8, IC₅₀: 280 nM CDK8, Kd: 0.83 μM							CDK19, Kd: 0.31 μM
CDK9-IN-9		CDK2, IC₅₀: 155 nM							CDK9, IC₅₀: 1.8 nM
CDK9-IN-34									CDK9, IC₅₀: 0.25 μM
ZLHQ-5f		CDK2/CycA2, IC₅₀: 0.145 μM
Anticancer agent 264	CDK1/cyclinB1	CDK2/cyclinE
CDK2-IN-37		CDK2
CDK7-IN-29							CDK7, IC₅₀: 1.4 nM
CDK8-IN-5								CDK8, IC₅₀: 72 nM
CDK4/6-IN-21 maleate				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
CDK-TCIP1									CDK9
Haspin-IN-2																	CLK1, IC₅₀: 445 nM
PARP1/CDK12-IN-1											CDK12, IC₅₀: 285 nM
BLINK15	CDK1/Cly Y, IC₅₀: 35.84 nM	CDK2/ClyA2, IC₅₀: 44.12 nM			CDK5/p35, IC₅₀: 29.34 nM Cdk5/p25, IC₅₀: 12.08 nM				CDK9/Cyclin T, IC₅₀: 74.63 nM
ZDLD13				CDK4/CycD3, IC₅₀: 0.38 μM
PROTAC FLT3/CDKs degrader-1		CDK2, DC₅₀: 18.73 nM
CDK-IN-18		CDK2		CDK4		CDK6
ALK-IN-29		CDK2
CDK4/6/HDAC-IN-1	CDK1, IC₅₀: 55.6 nM			CDK4, IC₅₀: 7.23 nM		CDK6, IC₅₀: 13.2 nM CDK6, IC₅₀: 48.38 nM
CDK7-IN-30	CDK1, IC₅₀: >10000.00 nM	CDK2, IC₅₀: 734.55 nM	CDK3, IC₅₀: 370.40 nM	CDK4, IC₅₀: 644.80 nM	CDK5, IC₅₀: 3678.50 nM	CDK6, IC₅₀: 1345.50 nM	CDK7, IC₅₀: 7.21 nM		CDK9, IC₅₀: 704.3 nM
CDK2-IN-41		CDK2
CDK4/6/BRD4-IN-1				CDK4, IC₅₀: 85 nM		CDK6, IC₅₀: 106 nM
CDK9-IN-22		cdk2/cyclin A, IC₅₀: 876.2 nM							CDK9/cyclinT1, IC₅₀: 10.4 nM
CDK7-IN-27		CDK2, IC₅₀: 19.4 nM					CDK7, IC₅₀: 3 nM
CDK4/6-IN-19				CDK4, IC₅₀: 0.2 nM		CDK6, IC₅₀: 5.0 nM
PSTAIR																CDC28
Antitumor agent-174	CDK1/cyclinB1
CDK8-IN-18								CDK8, IC₅₀: 43 μM
Ulecaciclib		cdk2/cyclin A, Ki: 0.62 μM		Cdk4/cyclin D1, Ki: 0.2 nM		cdk6/cyclin D3, Ki: 3 nM	cdk7-cyclin H, Ki: 0.63 μM
BLINK11	CDK1/Cly Y, IC₅₀: 39.34 nM	CDK2/ClyA2, IC₅₀: 83.43 nM			CDK5/p35, IC₅₀: 17.09 nM Cdk5/p25, IC₅₀: 14.69 nM				cdk9-cyclin T, IC₅₀: 83.43 nM
GSK3-IN-10				CDK4, IC₅₀: 3800 nM													CLK1, IC₅₀: 620 nM CLK4, IC₅₀: 760 nM CLK2, IC₅₀: 800 nM
CDK2-IN-14-d₃		CDK2
CDK2/4-IN-1		CDK2		CDK4
CDK1-IN-4	CDK1, IC₅₀: 44.52 nM	CDK2, IC₅₀: 621.93 nM			CDK5, IC₅₀: 135.22 nM
Isosilybin B (Standard)		CDK2		CDK4
CDK2-IN-28		CDK2, Ki: 1 nM ([1])			CDK5, Ki: 15.8 nM ([1])		CDK7, Ki: 54.7 nM ([1])		CDK9, Ki: 12.8 nM ([1])
DDO-6079																CDC37
PROTAC CDK9/CycT1 Degrader-2									CDK9, IC₅₀: 45 nM
CDK4/6-IN-23						CDK6, IC₅₀: 11 nM
VEGFR-2-IN-69		CDK2		CDK4		CDK6
CDK6/9-IN-2						CDK6, IC₅₀: 15 nM			CDK9, IC₅₀: 22 nM
KB-0742 hydrochloride	CDK1/cyclin A, IC₅₀: 2980 nM	cdk2/cyclin A, IC₅₀: 397 nM	CDK3/Cyclin E, IC₅₀: 1420 nM	Cdk4/cyclin D1, IC₅₀: 3130 nM	Cdk5/p25, IC₅₀: 1820 nM	CDK6/cycD1, IC₅₀: 3950 nM	CDK7/cyclin H, IC₅₀: 1510 nM	CDK8/cyclin C, IC₅₀: >10000 nM	CDK9/cyclinT1, IC₅₀: 6 nM
CDK19 Probe 1															CDK19, IC₅₀: 1.01 μM
CDK-IN-12				CDK4, IC₅₀: <20 nM		CDK6, IC₅₀: <20 nM
HDAC1/CDK7-IN-1							CDK7, IC₅₀: 893 nM
TMX-2138	CDK1/cyclinB, IC₅₀: 8.7 nM	CDK2/cyclinA, IC₅₀: 10.9 nM		CDK4/cyclinD1, IC₅₀: 901 nM	Cdk5/p25, IC₅₀: 7.0 nM	CDK6/cyclinD1, IC₅₀: 465 nM	CDK7/cyclin H, IC₅₀: 286 nM		CDK9/cyclinT1, IC₅₀: 25.7 nM
CDK12-IN-4		CDK2/cyclinE, IC₅₀: >20 μM							CDK9/cyclinT1, IC₅₀: >20 μM		CDK12, IC₅₀: 0.641 μM
SLM6									CDK9/cyclinT1, IC₅₀: 133 nM
NUAK1-IN-1				CDK4
P-gp/CDK2-IN-1		CDK2
Cdc7-IN-15																Cdc7
CDK9-IN-19									CDK9/cyclinT1, IC₅₀: 2 nM
Haspin-IN-1																	CLK1, IC₅₀: 221 nM
CDK8-IN-10								CDK8, IC₅₀: 8.25 nM
CDK2/4/6-IN-1		CDK2, IC₅₀: 2.5 nM		CDK4, IC₅₀: 23.7 nM		CDK6, IC₅₀: 44.3 nM
CDK9-IN-23									CDK9, IC₅₀: <20 nM
CDK7/9-IN-1							CDK7, IC₅₀: 5.74-65.6 nM		CDK9, IC₅₀: 2.14 μM
Anticancer agent 30		CDK2
PROTAC CDK9 degrader-6									CDK9₄₂, DC₅₀: 0.03 μM CDK9₅₅, DC₅₀: 0.05 μM
CDK4/6-IN-7				CDK4, IC₅₀: 1.58 nM		CDK6, IC₅₀: 4.09 nM
CLZX-205									CDK9, IC₅₀: 2.9 nM
PI3Kα-IN-26		CDK2/CycA2, IC₅₀: 3.96 μM						CDK8/cyclin C, IC₅₀: 137.20 nM
CDK4/6-IN-16				CDK4, IC₅₀: 13 nM
CDK4/9-IN-1				CDK4, IC₅₀: 23 nM					CDK9, IC₅₀: 12 nM
CDK2-IN-26		CDK2
CDK4/6-IN-10				CDK4, IC₅₀: 22 nM		CDK6/cyclinD1, IC₅₀: 10 nM
CDK2-IN-42											CDK12
KDM1/CDK1-IN-1	CDK1, IC₅₀: 0.078 ± 2. μM
CDK7-IN-8							CDK7, IC₅₀: 54.29 nM
CDK7-IN-7							CDK7, IC₅₀: <50 nM
CDK8-IN-6								CDK8, Kd: 13 nM
CDK9-IN-28									CDK9/cyclinT1
CDK4/6-IN-8				CDK4, IC₅₀: 5.01 nM		CDK6, IC₅₀: 3.97 nM
PF-06842874				CDK4/cyclinD1, Ki: 62 nM		cdk6/cyclin D3, Ki: 130 nM
CDK7-IN-5							CDK7, IC₅₀: <100 nM
PROTAC CDK9 degrader-5									CDK9₄₂, DC₅₀: 0.10 μM CDK9₅₅, DC₅₀: 0.14 μM
CDK8/19-IN-3								CDK8							CDK19
CDKI-83	CDK1/B, Ki: 72 nM	CDK2/E, Ki: 232 nM		CDK4/D, Ki: 290 nM			CDK7/H, Ki: 405 nM		CDK9/T1, Ki: 21 nM
CDK5-IN-4		CDK2, IC₅₀: 6.24 ± 2.8 μM			CDK5, IC₅₀: 9.8 ± 2.29 μM				CDK9, IC₅₀: 1.76 ± 0.3 μM
G721-0282				CDK4		CDK6
CDK2-IN-8		CDK2, IC₅₀: 1.74 μM
(S)-LY3177833																Cdc7
CDK12/13-IN-2											CDK12, IC₅₀: 15.5 nM	CDK13, IC₅₀: 12.2 nM
Cdc7-IN-19																Cdc7, IC₅₀: 1.49 nM
CDK1/2/4-IN-1	CDK1, IC₅₀: 1.47	CDK2, IC₅₀: 0.78		CDK4, IC₅₀: 0.87
CGP-74514 hydrochloride	CDK1/cyclinB1, IC₅₀: 25 nM
SZ-015268							CDK7, IC₅₀: 23.56 nM
CDK2-IN-12		CDK2, IC₅₀: 11.6 μM							CDK9, IC₅₀: >12.5 μM
CP-07									CDK9
CDK7-IN-31							CDK7, Kd: 0.18 nM
SHP2/CDK4-IN-1				CDK4, IC₅₀: 18.2 ± 1.3 nM
CDK4/6-IN-20				CDK4, IC₅₀: 1.9 nM		CDK6, IC₅₀: 14.2 nM
CDK9 degrader-1									CDK9, DC₅₀: 0.4073 μM
Multi-kinase-IN-4		CDK2, IC₅₀: 2.09 μM
Cdc7-IN-12																Cdc7, IC₅₀: <1 nM
YX0798									CDK9, Kd: 0.28 nM
YJZ5118											CDK12	CDK13
CDK2-IN-44		CDK2
CDK-IN-14		CDK2/CycA2, IC₅₀: 0.097 μM
CDK2-IN-18		CDK2/cyclinE, IC₅₀: 8 nM		Cdk4/cyclin D1, IC₅₀: 46 nM
CDK7-IN-32							CDK7
EGFR-IN-45		CDK2, IC₅₀: 1.6 μM
CDK7-IN-20	CDK1, IC₅₀: 3375 nM	CDK2, IC₅₀: 823 nM	CDK3, IC₅₀: 1837 nM		CDK5, IC₅₀: >10,000 nM	CDK6, IC₅₀: 950 nM	CDK7, IC₅₀: 4 nM		CDK9, IC₅₀: 526 nM		CDK12, IC₅₀: >10,000 nM
ZDLD20				CDK4/CycD3, IC₅₀: 6.51 μM																					99.84%
CDK9-IN-33		CDK2, IC₅₀: 316.30 nM		CDK4, IC₅₀: 1771.00 nM		CDK6, IC₅₀: >10000 nM	CDK7, IC₅₀: 160 nM		CDK9, IC₅₀: 17.44 nM
CDK8-IN-19		CDK2/CycA2, IC₅₀: 1.13 μM						CDK8/cyclin C, IC₅₀: 25.08 nM
LZ9	CDK1 cyclin B1/CDC2
3-Methylthienyl-carbonyl-JNJ-7706621	CDK1/cyclinB, IC₅₀: 6.4 nM	CDK2/cyclinA, IC₅₀: 2 nM		CDK4, IC₅₀: 0.11 μM
CDK-IN-9		CDK2/E, IC₅₀: 4 nM			Cdk5/p25, IC₅₀: 39 nM				CDK9/T1, IC₅₀: 20 nM		CDK12/K, IC₅₀: 64 nM	CDK13/K, IC₅₀: 22 nM
Autophagy agonist-1				CDK4
CDK9 autophagic degrader 1									CDK9
Wogonin (Standard)								CDK8
ARN25499																Cdc42
CLK1/2-IN-3																	CLK1, IC₅₀: 1.1 nM CLK2, IC₅₀: 2.1 nM
Carbonic anhydrase inhibitor 33						CDK6, IC₅₀: 0.069 μM
CDK2-IN-29		CDK2, IC₅₀: 96 nM		CDK4, IC₅₀: 360 nM
Carbonic anhydrase inhibitor 14		CDK2, IC₅₀: 20.3 μM
CDK9-IN-37									CDK9, EC₅₀: 5.5 nM
Cdc7-IN-14																Cdc7, IC₅₀: <1 nM
YY173				CDK4, IC₅₀: 7.7 nM		CDK6, IC₅₀: 88 nM
Multi-kinase-IN-6		CDK2, IC₅₀: 0.71 μM
FLT3/ITD-IN-4														CDK16/Cyclin Y, EC₅₀: 1768 nM
Anticancer agent 29	CDK1/cyclinB1, IC₅₀: 0.127 μM	CDK2/cyclinE, IC₅₀: 0.054 μM		CDK4, IC₅₀: 0.129 μM		CDK6, IC₅₀: 0.396 μM
CDK9-IN-36									CDK9, IC₅₀: 1.2 nM
CDK9-IN-24									CDK9
CDK2-IN-20		CDK2/cyclinE, IC₅₀: 0.219 μM
CDK9-IN-40									CDK9, IC₅₀: 5.5 nM
XL413 hydrochloride																Cdc7, IC₅₀: 3.4 nM
CDK2-IN-7		CDK2/cyclinE, IC₅₀: 50 nM
CDK2/9-IN-1		CDK2, IC₅₀: 0.004 μM							CDK9, IC₅₀: 0.009 μM
CDK8/19-IN-2								CDK8/CycC, IC₅₀: 2.08 nM							CDK19/CycC, IC₅₀: 2.49 nM
CDK2-IN-45		CDK2, IC₅₀: 0.64 μM
CDK9/HDAC1/HDAC3-IN-1									CDK9, EC₅₀: 0.17 μM
CDK12-IN-8											CDK12
CKI-7																Cdc7
CDK7-IN-28		cdk2/cyclin A, IC₅₀: 6224 nM					CDK7/Cyclin H/MNAT1, IC₅₀: ＜5 nM					CDK13/Cyclin K, IC₅₀: 152 nM
Aloisine RP106	Cdk1/cyclin B, IC₅₀: 0.7 μM				Cdk5/p25, IC₅₀: 1.5 μM
Aloisine A	CDK1/cyclinB, IC₅₀: 0.15 μM	CDK2/cyclinA, IC₅₀: 0.12 μM CDK2/cyclinE, IC₅₀: 0.4 μM			CDK5/p35, IC₅₀: 0.16 μM
CDK9-IN-41									CDK9, IC₅₀: 192.81 nM																98.84%
CDK7-IN-16							CDK7, IC₅₀: 1~10 nM
FLT3/CDK4-IN-1				CDK4, IC₅₀: 7 nM
BMI-1026	CDK1, IC₅₀: 2.3 nM
CDK2-IN-43		Cdk2/cyclin E2, IC₅₀: 6 nM
CDK12-IN-7		CDK2, IC₅₀: 196 nM									CDK12, IC₅₀: 42 nM
CDK2-IN-9		CDK2, IC₅₀: 0.63 μM
Cdc7-IN-13																Cdc7, IC₅₀: <1 nM
CDK4/6-IN-21				CDK4, IC₅₀: 3.88 nM		CDK6, IC₅₀: 3.31 nM
CDK8-IN-17								CDK8, IC₅₀: 9 nM
CDK2-IN-15		CDK2, IC₅₀: 2.9 μM
P162-0948								CDK8, IC₅₀: 50.4 nM
LDC3140							CDK7, IC₅₀: <5 nM
SHR5428	CDK1, IC₅₀: >100 μM	CDK2, IC₅₀: 8.99 μM		CDK4, IC₅₀: 3.87 μM		CDK6, IC₅₀: 5.89 μM	CDK7, IC₅₀: 0.005 μM		CDK9, IC₅₀: 8.30 μM		CDK12, IC₅₀: 1.11 μM
AG-012986	Cdk1/cyclin B, Ki: 44 nM	cdk2/cyclin A, Ki: 94 nM		CDK4, Ki: 9.2 nM	CDK5/p35, IC₅₀: 22 nM				CDK9/Cyclin T, IC₅₀: 4 nM
VCC972839:01									CDK9, IC₅₀: 7 nM
CDK9-IN-32									CDK9
Cdc7-IN-18																Cdc7, IC₅₀: 1.29 nM
TMX-3013	CDK1, IC₅₀: 0.9 nM	CDK2, IC₅₀: <0.5 nM		CDK4, IC₅₀: 24.5 nM	CDK5, IC₅₀: 0.5 nM	CDK6, IC₅₀: 15.6 nM
CDK/HDAC-IN-2	CDK1, IC₅₀: 8.63 nM	CDK2, IC₅₀: 0.30 μM		CDK4, IC₅₀: >1000 nM		CDK6, IC₅₀: >1000 nM	CDK7, IC₅₀: >1000 nM
ZLWT-37		CDK2, IC₅₀: 0.054 μM							CDK9, IC₅₀: 0.002 μM
CDK4/6-IN-14	CDK1, IC₅₀: >10000 nM	CDK2, IC₅₀: 1045 nM		CDK4, IC₅₀: 10 nM		CDK6, IC₅₀: 16 nM	CDK7, IC₅₀: 2595 nM		CDK9, IC₅₀: 2664 nM
CLK1/4-IN-1																	CLK1, IC₅₀: 9.7 nM CLK4, IC₅₀: 6.6 nM
CDK9/PARP-IN-1									CDK9, IC₅₀: 118 nM
CDK7-IN-10							CDK7, IC₅₀: ＜100 nM
CDK2-IN-36		CDK2
CDK5-IN-2		CDK2/CycA, IC₅₀: 23 nM			Cdk5/p25, IC₅₀: 0.2 nM
CDK7-IN-6							CDK7, IC₅₀: ≤100 nM
CDK8-IN-7								CDK8, Kd: 3.5 nM
HQY1428											CDK12
CDK12/13-IN-3											CDK12, IC₅₀: 107.4 nM	CDK13, IC₅₀: 79.4 nM
CDK8-IN-15								CDK8, IC₅₀: 57 nM
KWZY-11						CDK6, IC₅₀: 13.3 nM
NUAK1-IN-2		CDK2		CDK4		CDK6
CDK4/6-IN-18				CDK4		CDK6
Avotaciclib sulfate	CDK1
CDK2/PIM1-IN-1		CDK2, IC₅₀: 0.27 μM
PPA-037											CDK12/Cyclin K
PROTAC CDK9 degrader-8									CDK9, IC₅₀: 0.01 μM
CDK11A Human Pre-designed siRNA Set A																								PITSLRE
EF-4-177		CDK2/cyclinE, IC₅₀: 87 nM
Tabersonine hydrochloride				CDK4
Cdk10 Mouse Pre-designed siRNA Set A																			CDK10
JTK-101									CDK9/cyclinT1
Cdk15 Rat Pre-designed siRNA Set A																				CDK15
Cdk20 Rat Pre-designed siRNA Set A																							CDK20
Olomoucine II	Cdk1/cyclin B, IC₅₀: 7.6 μM	CDK2/cyclinE, IC₅₀: 0.1 μM		CDK4/cyclinD1, IC₅₀: 19.8 μM			CDK7/cyclin H, IC₅₀: 0.45 μM		CDK9/cycT, IC₅₀: 0.06 μM
Cdk18 Rat Pre-designed siRNA Set A																						CDK18
2-Cyanoethylalsterpaullone	Cdk1/cyclin B, IC₅₀: 0.23 nM
CCT68127		CDK2					CDK7		CDK9
Alisol B 23-acetate (Standard)				CDK4		CDK6
CDK2-IN-27	CDK1/cyclinB1, IC₅₀: >10-20 nM nM	CDK2/cyclin E1, IC₅₀: <10 nM
CDK8-IN-16								CDK8, IC₅₀: 5.1 nM							CDK19, IC₅₀: 5.6 nM
Riviciclib	CDK1-Cyclin B, IC₅₀: 0.079 μM	cdk2-cyclin A, IC₅₀: 0.224 μM cdk2-cyclin E, IC₅₀: 2.540 μM		cdk4-cyclin D1, IC₅₀: 0.063 μM		cdk6-cyclin D3, IC₅₀: 0.396 μM			CDK9- Cyclin T1, IC₅₀: 0.020 μM CDK9-cyclin H, IC₅₀: 2.900 μM
Indirubin-3'-monoxime-5-sulphonic acid	CDK1, IC₅₀: 5 nM				CDK5, IC₅₀: 7 nM
Indirubin-5-sulfonate	Cdk1/cyclin B, IC₅₀: 55 nM	cdk2/cyclin A, IC₅₀: 35 nM CDK2/cyclinE, IC₅₀: 150 nM		Cdk4/cyclin D1, IC₅₀: 300 nM	CDK5/p35, IC₅₀: 65 nM
IIIM-290		CDK2/A, IC₅₀: 90 nM							CDK9/T1, IC₅₀: 94 nM

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

CDK Inhibitors

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z